Patents Assigned to Kringle Pharma Inc.
  • Patent number: 10702582
    Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: July 7, 2020
    Assignee: KRINGLE PHARMA INC.
    Inventors: Kazuhiro Fukuta, Hayao Inoue
  • Publication number: 20190117732
    Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
    Type: Application
    Filed: December 28, 2018
    Publication date: April 25, 2019
    Applicant: KRINGLE PHARMA INC.
    Inventors: Kazuhiro FUKUTA, Hayao INOUE
  • Patent number: 10213485
    Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: February 26, 2019
    Assignee: KRINGLE PHARMA INC.
    Inventors: Kazuhiro Fukuta, Hayao Inoue
  • Publication number: 20170333527
    Abstract: The present invention provides a hepatocyte growth factor (HGF) preparation in the form of an injection or the like that is highly safe for central nerves and highly stable and can be used for intrathecal or intracerebroventricular administration or for administration into the spinal or cerebral parenchyma for the treatment of central nervous system diseases. The HGF preparation of the present invention contains an HGF protein as an active ingredient and lactose, glycine, sodium chloride, a pH buffering agent and a surfactant as additional ingredients.
    Type: Application
    Filed: August 27, 2015
    Publication date: November 23, 2017
    Applicant: KRINGLE PHARMA INC.
    Inventors: Kazuhiro FUKUTA, Hayao INOUE
  • Patent number: 8927493
    Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
    Type: Grant
    Filed: October 8, 2009
    Date of Patent: January 6, 2015
    Assignee: Kringle Pharma, Inc.
    Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
  • Publication number: 20140056910
    Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.
    Type: Application
    Filed: October 18, 2013
    Publication date: February 27, 2014
    Applicant: Kringle Pharma Inc.
    Inventors: Seiji YANO, Kunio MATSUMOTO
  • Patent number: 8575099
    Abstract: The present invention discloses an agent for treating a polyglutamine aggregation-caused disease or suppressing its onset, which comprises, as an active ingredient, (1) (i) HGF protein, (ii) a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein, or a salt of either of them, or (2) DNA containing (i) DNA encoding HGF protein, (ii) DNA encoding a partial peptide of HGF protein that is substantially equivalent in activity to HGF protein or (iii) DNA which encodes a protein or a peptide that is substantially equivalent in activity to HGF protein and hybridizes with DNA comprising a complementary base sequence of either of the above-mentioned DNAs under a stringent condition.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: November 5, 2013
    Assignees: Osaka University, Kringle Pharma Inc.
    Inventors: Toshikazu Nakamura, Hiroshi Funakoshi, Daisuke Miyazawa, Kunio Iwatani
  • Patent number: 8518880
    Abstract: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: August 27, 2013
    Assignees: Keio University, Osaka University, Kringle Pharma Inc.
    Inventors: Hideyuki Okano, Yoshiaki Toyama, Masaya Nakamura, Akio Iwanami, Kazuya Kitamura, Toshikazu Nakamura, Hiroshi Funakoshi, Keigo Hanada
  • Patent number: 8461112
    Abstract: The present invention relates to an HGF preparation comprising HGF and purified sucrose. The HGF preparation is characterized by being stable even after a long-term storage.
    Type: Grant
    Filed: April 29, 2009
    Date of Patent: June 11, 2013
    Assignee: Kringle Pharma Inc.
    Inventors: Kiichi Adachi, Keigo Hanada
  • Patent number: 8383588
    Abstract: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: February 26, 2013
    Assignee: Kringle Pharma Inc.
    Inventors: Jun Amano, Ken-ichi Ito, Kazuhiro Yamaura, Kunio Matsumoto, Toshikazu Nakamura
  • Patent number: 8278270
    Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: October 2, 2012
    Assignees: Kringle Pharma Inc., Osaka University
    Inventors: Toshikazu Nakamura, Kunio Matsumoto, Kazuhiro Fukuta, Kiichi Adachi, Daichika Hayata
  • Publication number: 20120064090
    Abstract: Provided are a pharmaceutical composition which enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, wherein the cancer has resistance to the molecular target drug, and a cancer therapeutic agent effective against a cancer having resistance to a molecular target drug, such as gefitinib and erlotinib. The pharmaceutical composition comprising an HGF-MET receptor pathway inhibitor enhances the sensitivity of a cancer to a molecular target drug, such as gefitinib and erlotinib, even though the cancer has resistance to the molecular target drug. The cancer therapeutic agent comprising a molecular target drug in combination with an HGF-MET receptor pathway inhibitor is effective against a cancer having resistance to the molecular target drug.
    Type: Application
    Filed: October 9, 2009
    Publication date: March 15, 2012
    Applicant: KRINGLE PHARMA INC.
    Inventors: Seiji Yano, Kunio Matsumoto
  • Publication number: 20120021040
    Abstract: Disclosed is a therapeutic agent effective for the fundamental treatment of a spinal cord injury and a demyelinating disease. Specifically disclosed are a therapeutic agent for a spinal cord injury and a therapeutic agent for a demyelinating disease, each of which comprises an HGF protein as an active ingredient.
    Type: Application
    Filed: August 27, 2009
    Publication date: January 26, 2012
    Applicants: KEIO UNIVERSITY, KRINGLE PHARMA, INC., OSAKA UNIVERSITY
    Inventors: Hideyuki OKANO, Yoshiaki TOYAMA, Masaya NAKAMURA, Akio IWANAMI, Kazuya KITAMURA, Toshikazu NAKAMURA, Hiroshi FUNAKOSHI, Keigo HANADA
  • Publication number: 20110312887
    Abstract: An object of the present invention is to provide a drug for promoting the regeneration of tendon-bone junction tissue or ligament-bone junction tissue.
    Type: Application
    Filed: October 8, 2009
    Publication date: December 22, 2011
    Applicant: KRINGLE PHARMA, INC.
    Inventors: Katsuro Tomita, Hiroyuki Tsuchiya, Katsuhiko Kitaoka, Junsuke Nakase, Keigo Hanada, Kunio Matsumoto
  • Patent number: 8076289
    Abstract: A pharmaceutical preparation comprising a hepatocyte growth factor or a DNA molecule encoding the same and the like according to the present invention can suppress the fibrosis of a transplanted organ after organ transplantation. The present invention is useful in the fields of organ transplantation and regeneration therapy.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: December 13, 2011
    Assignee: Kringle Pharma Inc.
    Inventors: Jun Amano, Ken-ichi Ito, Kazuhiro Yamaura, Kunio Matsumoto, Toshikazu Nakamura
  • Patent number: 8003607
    Abstract: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the ? chain are deleted, and a ? chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the N-terminus of the ? chain are deleted; wherein (i) the peptide chain X has an amino-acid sequence of at least two residues, (ii) the peptide chain X can be cleaved by a protease reaction or a chemical reaction, and (iii) a protein obtained by cleaving at least one site of the peptide chain X has HGF action.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: August 23, 2011
    Assignees: Kringle Pharma Inc., Osaka University
    Inventors: Toshikazu Nakamura, Kunio Matsumoto, Kazuhiro Fukuta, Kiichi Adachi, Daichika Hayata
  • Publication number: 20100322998
    Abstract: A neovascularization promoting composition, a granulation formation-promoting composition and a preventive or curative composition for skin ulcer, comprising a human recombinant HGF wherein five amino acid residues are deleted in the first Kringle domain thereof. The provided compositions of the present invention are useful as a drug capable of promoting granulation formation and neovascularization and being effective in tissue restoration, especially as a preventive and curative agent for skin ulcer.
    Type: Application
    Filed: July 23, 2010
    Publication date: December 23, 2010
    Applicants: KRINGLE PHARMA INC.
    Inventors: Toshikazu Nakamura, Saho Yoshida, Kunio Matsumoto, Satoshi Itami, Kunihiko Yoshikawa
  • Patent number: 7838494
    Abstract: The present invention provides an agent comprising HGF for inducing differentiation of bone marrow cells into alveolar cells. The present invention also provides an HGF-containing agent for alveolar formation in pulmonary emphysema and the like in which alveoli are destroyed.
    Type: Grant
    Filed: March 7, 2005
    Date of Patent: November 23, 2010
    Assignees: Tohoku Technoarch Co., Ltd., Kringle Pharma Inc.
    Inventors: Hiroshi Kubo, Kota Ishizawa, Hidetada Sasaki, Toshikazu Nakamura
  • Publication number: 20100279934
    Abstract: Aspects of this invention relate to compositions and methods for the stabilization, storage, and delivery of biologically active agents, in particular peptides and nucleic acids. Particularly preferred embodiments include compositions that comprise a recombinant naturally occurring human hepatocyte growth factor (HGF), such as dHGF, a five amino acid truncated HGF variant, and at least one monoglyceride that remains in crystalline form at body temperature. Optionally, a gelling agent such as, hydroxyethylcellulose, and/or an antipathogenic compound (e.g., bupivacaine) can be included in the composition. Methods of use of these compositions to improve, ameliorate, or treat skin conditions are also embodiments.
    Type: Application
    Filed: December 19, 2008
    Publication date: November 4, 2010
    Applicant: KRINGLE PHARMA, INC.
    Inventor: Ake Lindahl
  • Patent number: 7807177
    Abstract: The present invention provides a segment of glycosylation-deficient HGF having mutation(s) introduced into an amino acid sequence so as to prevent glycosylation at at least one glycosylation site of a hepatocyte growth factor (HGF), and a method of producing the same. The segment of glycosylation-deficient HGF of the present invention has the same activity as that of a segment of glycosylated HGF, therefore, it is useful as an alternate for a segment of glycosylated HGF.
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: October 5, 2010
    Assignees: Kringle Pharma Inc.
    Inventors: Toshikazu Nakamura, Kunio Matsumoto, Kazuhiro Fukuta